New pain pill AFA-281 takes first step in human safety trial
NCT ID NCT05547503
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested the safety and tolerability of a new drug called AFA-281 in 64 healthy volunteers. Participants received either a single dose or multiple doses over 14-21 days. The goal was to check for side effects and measure how the drug behaves in the body, not to treat pain. Results will help decide if further studies in people with pain are warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AFA-281
- What this could lead to
- If successful, this could pave the way for further studies testing AFA-281 as a potential treatment for nerve or inflammatory pain.
- What could go wrong
- This is a very early Phase 1 trial in healthy volunteers, not patients. It only checks safety and how the drug moves through the body, not whether it works for pain. Many early-stage drugs fail in later trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAIN, INFLAMMATORY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CenExcel CNS
Los Alamitos, California, 90720, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Fibromyalgia pain puzzle: researchers sort pain into types
- Could a pain device help rare brain disease sufferers?
- New Ketamine-Like drug could ease nerve pain without the high
- Scientists probe why spinal injury leads to debilitating nerve pain
- Hidden pain in liver patients: a new study investigates
- Ozone gas may ease chemo nerve pain, small trial hopes